Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

ClinicalTrials.gov ID: NCT06238778

Public ClinicalTrials.gov record NCT06238778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b Randomized, Double-blind Trial Comparing HDV-Insulin Lispro Versus Insulin Lispro Alone in Adults With Type 1 Diabetes Receiving Insulin Degludec

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.

Study identification

NCT ID
NCT06238778
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Diasome Pharmaceuticals
Industry
Enrollment
227 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2023 (Actual)
Primary completion
Oct 27, 2025 (Actual)
Completion
Dec 16, 2025 (Actual)
Last update posted
Jul 31, 2026

2023 – 2025

United States locations

U.S. sites
27
U.S. states
12
U.S. cities
26
Facility City State ZIP Site status
Marvel Clinical Research Huntington Beach California 92647 —
Pasadena Clinical Trials Pasadena California 91101 —
Diabetes Research Center Tustin California 92780 —
University of Colorado, Barbara Davis Center Denver Colorado 80045 —
East Coast Institute for Research Jacksonville Florida 32216 —
University of Miami Diabetes Research Institute Miami Florida 33136 —
Metabolic Research Institute West Palm Beach Florida 33401 —
Atlanta Diabetes Associates Atlanta Georgia 30318 —
East Coast Institute for Research Canton Georgia 30114 —
Physicians Research Associates, LLC Lawrenceville Georgia 30046 —
Endocrine Research Solutions, Inc. Roswell Georgia 30076 —
University of Chicago Kovler Diabetes Center Chicago Illinois 60637 —
Endeavor Health Skokie Illinois 60077 —
Indiana Medical Research Institute Merrillville Indiana 46410 —
SUNY Upstate Medical University Syracuse New York 13210 —
Asheville Clinical Research Asheville North Carolina 28803 —
UNC EnDO Clinical Research Unit Chapel Hill North Carolina 27514 —
Physician's East Greenville North Carolina 27834 —
University Hospitals Medical Center Cleveland Ohio 44106 —
Texas Diabetes & Endocrinology Austin Texas 78749 —
Tekton Research, LLC Irving Texas 75039 —
Tekton Research, LLC McKinney Texas 75069 —
Texas Diabetes % Endocrinology Round Rock Texas 78681 —
Clinical Trials of Texas San Antonio Texas 78229 —
Tekton Research, LLC San Antonio Texas 78251 —
Wasatch Clinical Research, LLC 310 Salt Lake City Utah 84107 —
Virginia Endocrinology Research Chesapeake Virginia 23321 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06238778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2026 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06238778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →